Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Unknown3
Recruiting3
Enrolling By Invitation1
Active Not Recruiting1

Clinical Trials (8)

Showing 8 of 8 trials
NCT05039866Enrolling By Invitation

Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT06512571RecruitingPrimary

CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study

NCT06226987RecruitingPrimary

Molecular Imaging in Fabry Disease of the Heart

NCT04943991Not ApplicableActive Not Recruiting

Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score

NCT05413876Unknown

Fabry Exercise Intolerance Study

NCT03362164Recruiting

Evaluation of HEArt invoLvement in Patients With FABRY Disease

NCT03222336UnknownPrimary

Natural History in Fabry Patients With IVS4+919G>A Mutation

NCT01442350UnknownPrimary

Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers

Showing all 8 trials

Research Network

Activity Timeline